ArticleCell biochemistry and biophysics2026
Fisetin-loaded Nanoemulsion and Fecal Microbiome Extract Enhance In Vitro Inhibition of Non-Small Cell Lung Cancer Progression.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. While conventional treatments such as chemotherapy and radiotherapy are highly established, adverse effects and therapy resistance necessitate the exploration of novel therapeutic strategies. This study investigates the in vitro anti-cancer potential of the flavonoid fisetin and its nanoemulsion formulation (FNE) in NSCLC, alongside fecal microbiome extract (FME) as a potential adjunct therapy. In vitro functional assays demonstrated that while pure fisetin powder did not significantly inhibit NSCLC cell proliferation, colony formation nor cell migration, FNE and FME exhibited notable cytotoxic effects. Protein array analysis identified significant downregulation of 22 key oncogenic proteins implicated in lung cancer tumour development, epithelial-mesenchymal transition, tumour microenvironment, immunomodulation, therapy resistance, and metastasis. Importantly, the computational analysis supported these results by identifying fisetin-associated genes that correspond to the experimentally downregulated proteins. Computational in silico analysis of fisetin-associated genes identified multiple lung cancer targets including IL6, SERPINE1, PDGFA, MMP3, MST1, MET, and ENPP2. These findings highlight the enhanced therapeutic efficacy achieved through a phytoceutical-loaded nanoemulsion and microbiome-modulated anti-cancer mechanisms, with improved outcomes when combining FNE and FME treatments. The integration of phytoceuticals and microbiome research represents a promising avenue for advancing NSCLC treatment strategies and overcoming current therapeutic limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.